Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P0C263
UPID:
SBK2_HUMAN
Alternative names:
SH3-binding domain kinase family member 2; Sugen kinase 69
Alternative UPACC:
P0C263
Background:
Serine/threonine-protein kinase SBK2, also known by its alternative names SH3-binding domain kinase family member 2 and Sugen kinase 69, plays a crucial role in cellular signaling pathways. This kinase is involved in the phosphorylation of serine and threonine amino acid residues, a key process in the activation and regulation of various proteins within the cell.
Therapeutic significance:
Understanding the role of Serine/threonine-protein kinase SBK2 could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways suggests that modulating its activity could offer new avenues for treating diseases where these pathways are dysregulated.